Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Elite Pharma Inc (OP: ELTP )

0.3786 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 24, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open 0.3786
Bid (Size) N/A (0)
Ask (Size) N/A (0)
Prev. Close 0.3786
Today's Range 0.3786 - 0.3786
52wk Range 0.0821 - 0.4199
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Elite Pharmaceuticals Announces Commercial Launch of Generic Methotrexate Sodium
Northvale, New Jersey--(Newsfile Corp. - August 27, 2024) - Elite Pharmaceuticals, Inc. (OTCQB: ELTP) ("Elite" or the "Company"), a specialty... 
Via Newsfile
ELTP Stock Earnings: Elite Pharmaceuticals Reported Results for Q1 2025
Elite Pharmaceuticals just reported results for the first quarter of 2025. 
Via InvestorPlace

Performance

YTD
+171.79%
+171.79%
1 Month
+58.28%
+58.28%
3 Month
+107.11%
+107.11%
6 Month
+148.43%
+148.43%
1 Year
+320.67%
+320.67%

More News

Read More
Elite Pharmaceuticals, Inc. Reports Financial Results for the First Quarter of Fiscal Year 2025 Ended June 30, 2024 and Provides Conference Call Information
Via Newsfile
Elite Pharmaceuticals, Inc. to Host Conference Call to Provide Corporate Update and Discuss First Quarter 2025 Financial Results on August 15, 2024
Via Newsfile
ELTP Stock Earnings: Elite Pharmaceuticals Reported Results for Q4 2024
Via InvestorPlace
Elite Pharmaceuticals, Inc. Reports Financial Results for Third Quarter of Fiscal Year 2024 ended December 31, 2023 and Provides Conference Call Information
Via ACCESSWIRE
Elite Pharmaceuticals, Inc. Reports Financial Results for Second Quarter of Fiscal Year 2024 ended September 30, 2023 and Provides Conference Call Information
Via ACCESSWIRE
Elite Pharmaceuticals, Inc. Reports Financial Results for First Quarter of Fiscal Year 2024 ended June 30, 2023 and Provides Conference Call Information
Via ACCESSWIRE
Elite Pharmaceuticals, Inc. Reports Financial Results for the Fiscal Year Ended March 31, 2024 and Provides Conference Call Information
Via Newsfile
Treasure Hunt: 7 Penny Stocks Wall Street Hasn’t Discovered Yet
Via InvestorPlace
Elite Pharmaceuticals, Inc. to Host Conference Call to Provide Corporate Update and Discuss Fiscal Year 2024 Financial Results on July 2, 2024
Via Newsfile
Exposures Product Safety
7 Strong Buy Penny Stocks to Buy Now: June 2024
Via InvestorPlace
Elite Pharmaceuticals Receives FDA Approval for Generic Methotrexate
Via ACCESSWIRE
Elite Pharmaceuticals, Inc. to Host Conference Call to Provide Corporate Update and Discuss First Quarter 2024 Financial Results on August 15, 2023
Via ACCESSWIRE
Elite Pharmaceuticals, Inc. to Host Conference Call to Provide Corporate Update and Discuss Third Quarter 2024 Financial Results on February 15, 2024
Via ACCESSWIRE
Elite Pharmaceuticals Files ANDA with US FDA to Market Central Nervous System Stimulant
Via ACCESSWIRE
Elite Pharmaceuticals Announces First Product Shipment of Generic Adderall XR(R) to Marketing Partner Prasco, LLC
Via ACCESSWIRE
Small Stocks, Big Potential: 7 Penny Stocks Poised for Major Gains in 2024
Via InvestorPlace
Elite Pharmaceuticals, Inc. to Host Conference Call to Provide Corporate Update and Discuss Second Quarter 2024 Financial Results on November 15, 2023
Via ACCESSWIRE
7 Penny Stocks With Promising Potential Catalysts in 2024
Via InvestorPlace
Q4 Stock Predictions: 7 Penny Stocks Ready to Roar Into 2024
Via InvestorPlace
Elite Pharmaceuticals Files ANDA with US FDA to Market Opiate Analgesic Product
Via ACCESSWIRE
Elite Pharmaceuticals, Inc. Appoints Carter Ward as Chief Financial Officer
Via ACCESSWIRE
7 Up-and-Coming Penny Stocks to Put on Your Must-Buy List
Via InvestorPlace
Elite Pharmaceuticals Reports Positive Results from a Pivotal Bioequivalence Study
Via ACCESSWIRE
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.